Dorzagliatin

Dorzagliatin is an oral small molecule drug approved in China for the treatment of type 2 diabetes mellitus. It is a first-in-class glucokinase activator (GKA) and represents a novel approach to managing blood glucose levels by targeting a key enzyme in glucose metabolism.

Mechanism of Action

Dorzagliatin acts as a glucokinase activator (GKA). Glucokinase (GK) is a crucial enzyme that functions as a "glucose sensor" primarily in pancreatic beta cells and hepatocytes (liver cells). In pancreatic beta cells, GK activation enhances glucose metabolism, leading to increased glucose-stimulated insulin secretion. In the liver, GK activation promotes the uptake of glucose from the bloodstream and its subsequent storage as glycogen or metabolism. By selectively activating glucokinase in a glucose-dependent manner, dorzagliatin aims to restore the impaired glucose-sensing function often observed in individuals with type 2 diabetes, thereby improving overall glycemic control.

Therapeutic Use

Dorzagliatin is indicated for the management of type 2 diabetes mellitus to help lower and maintain blood glucose levels within a target range. Its unique mechanism of action addresses metabolic defects that contribute to hyperglycemia.

Development and Approval

Dorzagliatin was developed by Hua Medicine, a biopharmaceutical company. Following extensive clinical trials, primarily conducted in China, dorzagliatin received regulatory approval in China in late 2021 / early 2022. This approval made it the first glucokinase activator to be authorized for marketing globally, marking a significant advancement in the pharmacological treatment options for type 2 diabetes.

Adverse Effects

As with other medications for diabetes, dorzagliatin may be associated with certain adverse effects. The glucose-dependent nature of its action is designed to reduce the risk of severe hypoglycemia compared to some other types of insulin secretagogues. However, patients are typically advised to monitor for hypoglycemia and other potential side effects, which are generally consistent with those observed with other glucose-lowering agents.